Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial

BACKGROUND: Treatment and morbidity control of schistosomiasis relies on a single drug, praziquantel. Hence, there is a pressing need to develop additional therapeutics against schistosomiasis. The antimalarial drug mefloquine shows antischistosomal activity in animal models and clinical trials, whi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Keiser, Jennifer, Silué, Kigbafori D., Adiossan, Lukas K., N'Guessan, Nicaise A., Monsan, N'Chou, Utzinger, Jürg, N'Goran, Eliézer K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2014
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102459/
https://ncbi.nlm.nih.gov/pubmed/25033291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0002975
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller